rotigotine
Neupro	Pharmaceutical company: Schwarz Pharma www.schwarzusa.com

Pharmacologic classification: dopamine agonist
Therapeutic classification: antiparkinsonian
Pregnancy risk category: C

AVAILABLE FORMS
Transdermal system: 2 mg, 4 mg, 6 mg

INDICATIONS AND DOSAGES
Early-stage idiopathic Parkinson’s disease--
Adults: 2 mg transdermal system applied daily. May increase weekly by 2 mg; maximum dose 6 mg every 24 hours. Have patient rotate application site and remove old system before applying a new one.

CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with known hypersensitivity to drug or any of its components.
   Use cautiously in patients with a history of sulfite sensitivity, hypotension, heart failure, or renal insufficiency. Use cautiously during pregnancy.

INTERACTIONS
Drug-drug. Dopamine agonists such as antipsychotics or metoclopramide: May decrease effectiveness of rotigotine.

ADVERSE REACTIONS
CNS: headache, dizziness, fatigue, falling asleep suddenly, hallucinations, vertigo, somnolence, insomnia, compulsive behaviors.
CV: edema, hypotension, hypertension.
GI: nausea, vomiting, constipation, anorexia, dyspepsia, dry mouth.
Respiratory: sinusitis.
Other: back pain, arthralgia, increased sweating, application site reactions.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our Disclaimer .

© Copyright 2008 by Lippincott Williams & Wilkins